{"id":"iopamidol-injection-76","safety":{"commonSideEffects":[{"rate":null,"effect":"Contrast-induced nephropathy"},{"rate":null,"effect":"Allergic reaction (mild to severe)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Flushing and warmth sensation"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL1200932","moleculeType":"Small molecule","molecularWeight":"777.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iopamidol contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. It distributes throughout the vascular system and extracellular space, allowing visualization of blood vessels, organs, and tissues during angiography, CT, and other imaging studies. The 76% formulation refers to the iodine concentration by weight.","oneSentence":"Iopamidol is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:04.555Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contrast enhancement for angiography and vascular imaging"},{"name":"Contrast enhancement for computed tomography (CT) imaging"},{"name":"Contrast enhancement for urography and other radiographic procedures"}]},"trialDetails":[{"nctId":"NCT01402219","phase":"PHASE4","title":"Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients","status":"TERMINATED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2008-11","conditions":"Chronic Renal Disease","enrollment":204},{"nctId":"NCT00782639","phase":"PHASE4","title":"Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients","status":"TERMINATED","sponsor":"Bracco Diagnostics, Inc","startDate":"2009-03","conditions":"Chronic Renal Impairment, Diabetes Mellitus","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Isovue"],"phase":"marketed","status":"active","brandName":"Iopamidol injection 76%","genericName":"Iopamidol injection 76%","companyName":"Bracco Diagnostics, Inc","companyId":"bracco-diagnostics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iopamidol is a non-ionic iodinated contrast agent that increases radiodensity in blood vessels and tissues to enhance visualization during radiographic imaging procedures. Used for Contrast enhancement for angiography and vascular imaging, Contrast enhancement for computed tomography (CT) imaging, Contrast enhancement for urography and other radiographic procedures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}